Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Mirum Pharamceuticals (MIRM) PT Raised to $70 at Stifel
November 12, 2024 12:51 PM ESTStifel analyst Dae Gon Ha raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $70.00 (from $66.00) while maintaining a Buy rating.
The analyst comments "Commercial progress (Livmarli, Chenodal, Cholbam) is on a positive trajectory as implied by $90.3M in product revenue with guidance... More
